{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:45:41Z","timestamp":1786373141134,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>In the FSGS Clinical Trial, 22 cyclosporine-treated and 20 mycophenolate\/dexamethasone-treated patients experienced a complete or partial remission after 26 weeks, completed 52 weeks of treatment, and were studied through 78 weeks. Herein, changes in the urine protein\/creatinine ratio (UP\/C) and estimated GFR (eGFR) throughout the entire study period are defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, and measurements<\/jats:title>\n                    <jats:p>\n                      The FSGS Clinical Trial, which was conducted from November 2004 to January 2010, enrolled patients aged 2\u201340 years, with eGFR \u226540 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      and UP\/C &gt;1 mg\/mg after \u22654 weeks of corticosteroid therapy. Both groups received lisinopril or losartan throughout the study. UP\/C and eGFR were measured at 0, 26, 52, and 78 weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median UP\/C in the cyclosporine- and mycophenolate\/dexamethasone-responsive patients fell by 89.8% and 82.7% at 52 weeks; the fall was largely sustained at 78 weeks (74.7% and 80.3%, respectively). The mean eGFR fell by 19.4% in the cyclosporine group and rose by 7.0% in the mycophenolate mofetil\/dexamethasone group at 52 weeks, but subsequently rose by 16.4% and fell by 2.6%, respectively, in the two groups from 52 to 78 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this subset of responding FSGS patients, the improvement in UP\/C after cyclosporine or mycophenolate\/dexamethasone treatment was largely sustained for 6 months after therapy. Reduction in eGFR in the cyclosporine group was improved 6 months after cyclosporine was stopped although the levels were lower than baseline in seven patients who entered the study with decreased eGFR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.08330812","type":"journal-article","created":{"date-parts":[[2012,11,8]],"date-time":"2012-11-08T23:07:19Z","timestamp":1352416039000},"page":"211-218","source":"Crossref","is-referenced-by-count":18,"title":["Renal Function and Proteinuria after Successful Immunosuppressive Therapies in Patients with FSGS"],"prefix":"10.2215","volume":"8","author":[{"given":"Ronald J.","family":"Hogg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Radeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos N.","family":"Budisavljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Gassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie S.","family":"Gipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Ashley","family":"Jefferson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice G.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J.","family":"Kaskel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Moudgil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marva","family":"Moxey-Mims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Schelling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Schnaper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarak","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Trachtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Matti","family":"Vehaskari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Woronieki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Van Why","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zolotnitskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20230811","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/0272-6386(95)90120-5","article-title":"Focal segmental glomerular sclerosis in adults: Presentation, course, and response to treatment.","volume":"25","author":"Rydel","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"R2-8-20230811","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1681\/ASN.2004070593","article-title":"Focal and segmental glomerulosclerosis: Definition and relevance of a partial remission.","volume":"16","author":"Troyanov","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R3-8-20230811","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00467-005-2097-0","article-title":"Differential risk of remission and ESRD in childhood FSGS.","volume":"21","author":"Gipson","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"R4-8-20230811","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1046\/j.1523-1755.1999.07004.x","article-title":"Management of focal segmental glomerulosclerosis: Evidence-based recommendations.","volume":"70","author":"Burgess","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"R5-8-20230811","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/ki.1993.194","article-title":"A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome.","volume":"43","author":"Ponticelli","year":"1993","journal-title":"Kidney Int"},{"key":"R6-8-20230811","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1046\/j.1523-1755.1999.00778.x","article-title":"A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis.","volume":"56","author":"Cattran","year":"1999","journal-title":"Kidney Int"},{"key":"R7-8-20230811","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.ajkd.2003.09.027","article-title":"Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis.","volume":"43","author":"Heering","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R8-8-20230811","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1681\/ASN.V7156","article-title":"A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children.","volume":"7","author":"Lieberman","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"R9-8-20230811","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ki.2011.195","article-title":"Clinical trial of focal segmental glomerulosclerosis in children and young adults.","volume":"80","author":"Gipson","year":"2011","journal-title":"Kidney Int"},{"key":"R10-8-20230811","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ki.2010.485","article-title":"Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life.","volume":"79","author":"Gipson","year":"2011","journal-title":"Kidney Int"},{"key":"R11-8-20230811","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1542\/peds.58.2.259","article-title":"A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.","volume":"58","author":"Schwartz","year":"1976","journal-title":"Pediatrics"},{"key":"R12-8-20230811","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine.","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"R13-8-20230811","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/ki.2011.191","article-title":"Immunosuppressive treatment of focal segmental glomerulosclerosis: Lessons from a randomized controlled trial.","volume":"80","author":"Deegens","year":"2011","journal-title":"Kidney Int"},{"key":"R14-8-20230811","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00467-011-2056-x","article-title":"Renin-angiotensin-aldosterone system inhibitors in pediatric focal segmental glomerulosclerosis.","volume":"27","author":"Kangovi","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"R15-8-20230811","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/ndt\/17.11.2011","article-title":"Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome.","volume":"17","author":"Day","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"R16-8-20230811","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5414\/CNP62405","article-title":"Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis.","volume":"62","author":"Cattran","year":"2004","journal-title":"Clin Nephrol"},{"key":"R17-8-20230811","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/ndt\/gfm538","article-title":"Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: A pilot study.","volume":"23","author":"Senthil Nayagam","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R18-8-20230811","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00467-009-1356-x","article-title":"Mycophenolate mofetil in children with steroid\/cyclophosphamide-resistant nephrotic syndrome.","volume":"25","author":"de Mello","year":"2010","journal-title":"Pediatr Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201302000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:46Z","timestamp":1786369366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201302000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.08330812","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}